Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Cook

Cardiovascular Disease Tampa, FL Medical Doctor

NPI 1548605744 CMS profile 1483126

2 Tampa General Cir, Tampa, FL 33606

Open in the dashboard

General payments

$17,193

243 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Cook of Tampa, FL is reported in the CMS Open Payments database as having received $17,193 across 243 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,992 39
2024 General $3,271 36
2023 General $1,735 42
2022 General $4,731 59
2021 General $2,428 32
2020 General $362 4
2019 General $2,673 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Cook
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Christopher Cook were reported at $1,992. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Christopher Cook Cardiovascular Disease median Middle half National median
2019 $2,673 $450 $127–$1,392 $163
2020 $362 $242 $77–$751 $114
2021 $2,428 $335 $101–$1,037 $132
2022 $4,731 $395 $121–$1,211 $149
2023 $1,735 $443 $136–$1,283 $160
2024 $3,271 $450 $136–$1,323 $164
2025 $1,992 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $6,958 125 payments
  2. Abbott Laboratories $3,419 48 payments
  3. Biotronik Inc. $2,689 19 payments
  4. Boston Scientific Corporation $2,563 11 payments
  5. Atricure, Inc. $461 4 payments
  6. Medical Device Business Services, Inc. $210 2 payments
  7. Cardiva Medical, Inc. $203 3 payments
  8. ConvaTec Inc. $184 1 payment
  9. Medtronic Vascular, Inc. $183 23 payments
  10. Omega Medical Imaging, LLC $105 1 payment
  11. Other $217 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,928 199 payments
  2. Travel and Lodging $6,340 38 payments
  3. Education $778 5 payments
  4. Grant $147 1 payment
Products named General payments · program years 2019–2025
  1. General Therapies $2,281 7 payments
  2. ENSITE PRECISION $1,836 13 payments
  3. EVERA MRI XT DR SURESCAN $1,665 11 payments
  4. Micra $1,528 45 payments
  5. AZURE XT DR MRI SURESCAN $719 18 payments
  6. Edora 8 DR-T $477 2 payments
  7. Acticor 7 VR-T DX $477 2 payments
  8. Solia $477 2 payments
  9. Rivacor 7 DR-T $477 2 payments
  10. BioMonitor $477 2 payments
  11. Other $5,160 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

443

Median for Internal Medicine: 777

Drug cost

$151,316

Median for Internal Medicine: $73,373

Branded share of claims

31.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 86 $90,885
Xarelto Rivaroxaban Brand 28 $29,348
Entresto Sacubitril/Valsartan Brand 16 $24,987
Dofetilide Generic 20 $2,727
Flecainide Acetate Generic 61 $1,239
Metoprolol Succinate Generic 62 $903
Bumetanide Generic 11 $287
Diltiazem 24hr Er (Xr) Diltiazem Hcl Brand 11 $178
Carvedilol Generic 25 $177
Amiodarone Hcl Generic 16 $169

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$142,620

Medicare's payments for the services billed

Medicare patients

446

Average age 74

Services billed

1,746

194 women, 252 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 68%
Ischemic heart disease 60%
Arthritis 54%
Heart failure 50%
Chronic kidney disease 45%
Diabetes 35%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

243 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record